DE69625506D1 - Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung - Google Patents

Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung

Info

Publication number
DE69625506D1
DE69625506D1 DE69625506T DE69625506T DE69625506D1 DE 69625506 D1 DE69625506 D1 DE 69625506D1 DE 69625506 T DE69625506 T DE 69625506T DE 69625506 T DE69625506 T DE 69625506T DE 69625506 D1 DE69625506 D1 DE 69625506D1
Authority
DE
Germany
Prior art keywords
inhibitors
metalloproteinases
sulfur
tnf release
substituted peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69625506T
Other languages
English (en)
Other versions
DE69625506T2 (de
Inventor
Douglas Baxter
Gary Montana
Alan Owen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9520354.3A external-priority patent/GB9520354D0/en
Priority claimed from GBGB9607126.1A external-priority patent/GB9607126D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Application granted granted Critical
Publication of DE69625506D1 publication Critical patent/DE69625506D1/de
Publication of DE69625506T2 publication Critical patent/DE69625506T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DE69625506T 1995-10-05 1996-10-04 Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung Expired - Fee Related DE69625506T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9520354.3A GB9520354D0 (en) 1995-10-05 1995-10-05 Compounds
GBGB9607126.1A GB9607126D0 (en) 1996-04-04 1996-04-04 Compounds
PCT/GB1996/002438 WO1997012902A1 (en) 1995-10-05 1996-10-04 Thio-substituted peptides as inhibitors for metalloproteinases and tnf liberation

Publications (2)

Publication Number Publication Date
DE69625506D1 true DE69625506D1 (de) 2003-01-30
DE69625506T2 DE69625506T2 (de) 2003-07-24

Family

ID=26307887

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69625506T Expired - Fee Related DE69625506T2 (de) 1995-10-05 1996-10-04 Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung

Country Status (20)

Country Link
US (1) US5981490A (de)
EP (1) EP0859784B1 (de)
JP (1) JPH11512733A (de)
KR (1) KR100472752B1 (de)
CN (1) CN1145637C (de)
AT (1) ATE229972T1 (de)
AU (1) AU710072B2 (de)
BR (1) BR9610922A (de)
CA (1) CA2229434A1 (de)
CZ (1) CZ289711B6 (de)
DE (1) DE69625506T2 (de)
DK (1) DK0859784T3 (de)
ES (1) ES2186803T3 (de)
HU (1) HUP0003760A3 (de)
IL (1) IL123430A (de)
MX (1) MX9802680A (de)
NO (1) NO981520L (de)
NZ (1) NZ319222A (de)
PL (1) PL185312B1 (de)
WO (1) WO1997012902A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
ATE258063T1 (de) * 1997-03-03 2004-02-15 Darwin Discovery Ltd Selektive mmp inhibitoren mit verringerten nebenwirkungen
JP2002528461A (ja) * 1998-10-23 2002-09-03 ダーウィン・ディスカバリー・リミテッド 公知ペプチドメタロプロテイナーゼインヒビターの単一形態型
NL1013404C2 (nl) * 1999-10-27 2001-05-01 Dsm Nv Werkwijze voor de bereiding van een dipeptide en tussenproduct in een dergelijke werkwijze.
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU778368B2 (en) 2000-05-15 2004-12-02 Darwin Discovery Limited Hydroxamic acid derivatives
CA2436774A1 (en) 2001-01-30 2002-08-08 R. Michael Lawrence Sulfonamide lactam inhibitors of factor xa
US20040175419A1 (en) * 2001-04-26 2004-09-09 Sprockel Omar Leopold Control of compactibility through cystallization
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
WO2003048119A2 (en) * 2001-11-30 2003-06-12 Bristol-Myers Squibb Company Method of producing n-[(2s)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl]-l-leucyl-l-tert-leucine n-methylamide and intermediate thereof
US20060167334A1 (en) * 2003-06-26 2006-07-27 Anstadt Mark P Method and apparatus for direct mechanical ventricular actuation with favorable conditioning and minimal heart stress
EP1663201A4 (de) * 2003-07-15 2009-10-28 Korea Res Inst Of Bioscience Verwendung von neuen 2-oxo-heterozyklischen verbindungen sowie diesen enthaltenden pharmazeutischen zubereitungen
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CN103254291B (zh) * 2013-05-30 2014-06-25 常州亚当生物技术有限公司 肿瘤坏死因子-α多肽抑制剂及其应用
CN103285373A (zh) * 2013-05-30 2013-09-11 苏州普罗达生物科技有限公司 肿瘤坏死因子-α多肽抑制剂制备及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
WO1988006890A1 (en) * 1987-03-17 1988-09-22 Research Corporation Technologies, Inc. Synthetic inhibitors of mammalian collagenase
DE4311021A1 (de) * 1993-03-31 1994-10-27 Diagnostikforschung Inst Bifunktionelle Chelatbildner, deren Technetium- und Rhenium-Komplexe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Mittel
CA2170158A1 (en) * 1993-08-23 1995-03-02 Roy A. Black Inhibitors of tnf-alpha secretion
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
DK0784629T3 (da) * 1994-10-05 1999-10-25 Darwin Discovery Ltd Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteaser
US5994293A (en) * 1995-05-10 1999-11-30 Darwin Discovery Ltd. Peptidyl compounds and their therapeutic use
EP0824543A1 (de) * 1995-05-10 1998-02-25 Chiroscience Limited Peptide, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung

Also Published As

Publication number Publication date
CN1145637C (zh) 2004-04-14
KR19990063996A (ko) 1999-07-26
CA2229434A1 (en) 1997-04-10
PL185312B1 (pl) 2003-04-30
DK0859784T3 (da) 2003-04-22
CZ289711B6 (cs) 2002-03-13
WO1997012902A1 (en) 1997-04-10
ES2186803T3 (es) 2003-05-16
NZ319222A (en) 1999-09-29
NO981520D0 (no) 1998-04-03
NO981520L (no) 1998-04-03
DE69625506T2 (de) 2003-07-24
AU710072B2 (en) 1999-09-16
PL325824A1 (en) 1998-08-03
IL123430A0 (en) 1998-09-24
JPH11512733A (ja) 1999-11-02
US5981490A (en) 1999-11-09
CZ101798A3 (cs) 1998-08-12
EP0859784B1 (de) 2002-12-18
IL123430A (en) 2001-04-30
HUP0003760A2 (hu) 2001-04-28
ATE229972T1 (de) 2003-01-15
CN1198747A (zh) 1998-11-11
HUP0003760A3 (en) 2001-05-28
MX9802680A (es) 1998-11-30
KR100472752B1 (ko) 2006-01-27
BR9610922A (pt) 1999-12-21
EP0859784A1 (de) 1998-08-26
AU7139896A (en) 1997-04-28

Similar Documents

Publication Publication Date Title
DE69625506T2 (de) Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung
FI973360A0 (fi) Uusia dipeptidisiä amidiineja trombiininestäjiksi
NO20006717D0 (no) Proteaseinhibitorer
MY113489A (en) Reversible protease inhibitors
NO975742D0 (no) Reversible cysteinproteasehemmere
NO990548D0 (no) Inhibitorer for cystein-protease
PL319503A1 (en) Peptide compounds and their therapeutic application as inhibitors
ZA963619B (en) Protease inhibitor peptides
NO983688D0 (no) Serin-protease-inhibitorer
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
DE69533704D1 (de) Bradykinin-antagonist peptide mit n-substituierten glycinen
DE69832268D1 (en) Peptidyl-2-amino-1hydroxyalkansulfonsäuren als cystein-protease-inhibitoren
ATE226592T1 (de) Peptide, die metallproteinasen und die tnf- freisetzung hemmen, und ihre therapeutische verwendung
ATE277074T1 (de) Serine-protease-inhibitoren
ATE221080T1 (de) Serine-protease-inhibitoren
DE69617396D1 (de) T-Zellen beeinflussende Peptide
DE69428909D1 (de) Für die immun- und cns-therapie nutzbare, neuartige tripeptide
DK0830371T3 (da) Imidazo[1,5a]pyridin-afledte serinprotease-inhibitorer
ATE311440T1 (de) Bacillus-proteasen
ATE313624T1 (de) Bacillus proteasen
FI943259A (fi) Soluadheesion peptidi-inhibiittorit
BR9612344A (pt) Inibidores de proteases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee